Decision Impact Study of PreciseDx Breast

Not yet recruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

May 30, 2029

Conditions
Breast Cancer
Interventions
OTHER

Standard of Care

To use the patients age, tumor size, grade, and lymph node status and any genomic tests (i.e. OncotypeDx, MammaPrint etc to determine risk of recurrence,

All Listed Sponsors
collaborator

Mount Sinai Hospital, New York

OTHER

lead

Precise Dx, Inc.

INDUSTRY